Key takeaways
- KLOW is not one peptide. It is a premixed vial of BPC-157, TB-500, GHK-Cu and KPV.
- Each part has been studied on its own, mostly in animals and cell dishes.
- We found no published study and no registered trial of the blend itself.
- It is not FDA-approved, and it contains two peptides banned in sport.
KLOW keeps coming up in recovery forums as a "one shot does it all" option. The pitch is simple: take the popular GLOW repair blend and add an anti-inflammatory peptide called KPV.
The problem is that the research behind KLOW is really the research behind four separate molecules. Here is what each one has been studied for, and why that doesn't add up to evidence for the mix.
What is actually in a KLOW vial
KLOW is a single premixed vial of four peptides: BPC-157, TB-500, GHK-Cu and KPV. It is GLOW (the first three) with KPV added.
The split between the four is not always printed on the label. That matters, because the blend's effects, if any, depend on how much of each part you are getting.
Our site entry lists KLOW as not FDA-approved, with an evidence level of 2 out of 5. That rating reflects the weakest core parts, since there is no data on the blend. The half-life is mixed: each component behaves differently, and all are short-acting signals.
BPC-157: lots of rat studies, very few people
BPC-157 is a 15-amino-acid peptide based on a fragment of a stomach protein. In animals it has been studied for healing tendons, ligaments, muscle and bone, with proposed effects on blood-vessel growth and inflammation 1.
A 2025 systematic review in HSS Journal found 36 relevant studies. 35 were preclinical and only one was clinical, a small retrospective report on knee pain 1. The review found no clinical safety data and noted risks from unregulated manufacturing 1.
A newer 2026 review looked only at human studies. It found three, with 30 people in total, and rated the certainty of evidence as very low 2. Larger trials are now registered, including a placebo-controlled hamstring strain study that is recruiting 3.
TB-500: a fragment of a well-studied protein
TB-500 is a synthetic fragment of thymosin beta-4, a natural protein released after injury. Thymosin beta-4 binds actin, a building block inside cells, and helps cells move into damaged tissue 4.
Most of what is known comes from research on the full thymosin beta-4 protein, including early trials for wounds, eyes and the heart 4. TB-500 itself has far less direct research. A 2026 sports medicine review grouped it with other unapproved peptides that look promising in animals but lack rigorous human safety data 5.
GHK-Cu: the only part with human data, and it was topical
GHK-Cu is a small copper-carrying peptide found naturally in the body. Lab and animal work links it to collagen production, wound repair and blood-vessel growth 6. That review was written by researchers at a skin-care company, which is worth knowing.
The human studies that exist are small and used creams, not injections. In KLOW, GHK-Cu is injected, which is a different question. It is also the most likely cause of the stinging people report with the blend.
KPV: gut inflammation in mice
KPV is a three-amino-acid fragment of a natural hormone. In a 2008 study, it blocked the inflammation switch NF-κB in human gut cells in a dish 7.
Given in drinking water, it also reduced colitis in two mouse models 7. We are not aware of any published human trials, and we found none registered on ClinicalTrials.gov.
Why the parts don't prove the blend
Adding four studied molecules together does not give you a studied product. Nobody has tested whether these peptides boost each other, cancel each other out, or change each other's stability in the same vial.
We searched PubMed for studies combining these peptides and ClinicalTrials.gov for trials of KLOW. Both came up empty for the blend itself. The site entry puts it plainly: whether the mechanisms add together, or interfere, has not been studied.
There are practical downsides too. You cannot change one component without changing all four. Several parts promote blood-vessel growth or cell movement, which is a theoretical concern for anyone with a cancer history. GHK-Cu is a concern for people with copper-metabolism disorders like Wilson's disease.
KLOW also contains BPC-157 and TB-500, both banned by WADA. Any tested athlete should treat it as a banned product.
The bottom line
KLOW bundles four peptides with real but limited research, most of it in animals or cells. The only human data for any part is small, and for GHK-Cu it was topical. No study has tested the blend, so any benefit is assumed from the parts rather than shown.
This is educational information, not medical advice.
Sources
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review — HSS Journal, 2025. https://pubmed.ncbi.nlm.nih.gov/40756949/
- Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety — Acta Orthopaedica Belgica, 2026. https://pubmed.ncbi.nlm.nih.gov/42885452/
- BPC 157 for Acute Hamstring Muscle Strain Repair (NCT07437547) — ClinicalTrials.gov, 2026. https://clinicaltrials.gov/study/NCT07437547
- Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications — Expert Opinion on Biological Therapy, 2012. https://pubmed.ncbi.nlm.nih.gov/22074294/
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — Sports Medicine, 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data — International Journal of Molecular Sciences, 2018. https://pubmed.ncbi.nlm.nih.gov/29986520/
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation — Gastroenterology, 2008. https://pubmed.ncbi.nlm.nih.gov/18061177/
